Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma

Int J Urol. 2020 Nov;27(11):1024-1030. doi: 10.1111/iju.14352. Epub 2020 Sep 1.

Abstract

Objectives: To evaluate the relationship between residual urine volume, pyuria and bladder carcinoma recurrence.

Methods: The clinical data of 305 patients who had post-void residual urine volume measured and preoperative pyuria were retrospectively collected. The patients were classified into three risk groups based on the presence of residual urine and pyuria: good (negative residual urine and pyuria), intermediate (positive residual urine or pyuria) and poor (positive residual urine and pyuria). Predictive factors for intravesical recurrence-free survival were statistically analyzed using Cox proportional hazard models and Kaplan-Meier methods. The propensity score matching method was used to adjust the patients' backgrounds.

Results: The median follow-up period for all patients was 44 months. The presence of residual urine (P = 0.0164) and pyuria (P = 0.0233) were two independent prognostic factors for recurrence. After patients were classified into risk groups, the poor-risk group showed significantly shorter recurrence-free survival compared with that of the good- (P = 0.0002) and intermediate-risk groups (P = 0.0090). Even after matching, the presence of residual urine was related to short recurrence-free survival in male patients (P = 0.0012). When stratified by European Organization for Research and Treatment of Cancer risk groups, the presence of pyuria was related to short recurrence-free survival, especially for intermediate-risk patients without bacillus Calmette-Guérin treatment.

Conclusions: Post-void residual urine and preoperative pyuria are two risks for recurrence-free survival in non-muscle-invasive bladder cancer.

Keywords: bladder carcinoma; intravesical recurrence; non-muscle-invasive bladder cancer; pyuria; residual urine volume.

MeSH terms

  • Administration, Intravesical
  • BCG Vaccine / therapeutic use
  • Carcinoma*
  • Humans
  • Male
  • Neoplasm Recurrence, Local / epidemiology
  • Pyuria* / epidemiology
  • Pyuria* / etiology
  • Retrospective Studies
  • Urinary Bladder Neoplasms* / drug therapy
  • Urinary Bladder Neoplasms* / surgery

Substances

  • BCG Vaccine